An overall view of the process of the regulation of human iron metabolism

DOROTA FORMANOWICZ¹*, PIOTR FORMANOWICZ²,³

¹Department of Clinical Biochemistry and Laboratory Medicine, Poznań University of Medical Sciences, Poznań, Poland
²Institute of Computing Science, Poznań University of Technology, Poznań, Poland
³Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznań, Poland

* Corresponding author: doforman@ump.edu.pl

Abstract
Iron is a key component of many reactions in the human body, and by virtue of its ability to accept and donate electrons, it is required for a variety of normal cellular functions and is vital for proper growth and development. However, natural iron is rather insoluble and excess of iron is harmful since it can catalyze the formation of oxygen radicals. Fortunately, there are also mechanisms for protecting human body from excess 'free' iron. This is particularly important, given the fact that humans have very limited capacity to excrete iron. Therefore, cells have developed mechanisms to improve the solubility of iron to control intracellular iron concentrations at the point of iron absorption in the small intestine and other tissues. Since the described process is highly complex, a profound understanding of all the relationships occurring among its components is possible when a systems approach is applied to its analysis.

Key words: iron, homeostasis, transferrin, hepcidin, formal models

Introduction
In order to understand how human organism is able to maintain iron homeostasis, it is essential to consider the movement of iron between various compartments of the body. Under normal conditions, approximately 1-2 mg of iron per day enters the body via the cells of the proximal small intestine. This newly absorbed dietary iron is released into the bloodstream and binds to the serum transferrin (Tf). Approximately 3 mg of iron circulates bind to this protein, and as compared with 4 g of total body iron, it is a small portion. Iron ions bound to Tf are taken up by cells via transferrin receptor-1 (TfR1)-mediated endocytosis (Huebers and Finch, 1987). Most of this iron is taken up by the developing erythrocytes of the bone marrow and is used in the production of hemoglobin at a rate of approximately 22 mg of iron per day (Anderson et al., 2007). About 65-70% of total body iron exists in this form. Thereafter, old or damaged red blood cells are removed from the bloodstream by macrophages of the reticulo-endothelial system and iron is recycled back to plasma Tf. The total iron content of Tf corresponds to less than 0.1% of the body iron, but it is highly dynamic.

Iron can be used to synthesize many proteins, such as cytochromes containing heme, and proteins containing iron-sulfur (Fe-S) clusters. Approximately 10-15% of body iron is present in such proteins, with up to 80% of it found in muscle cell myoglobin. The remaining 20% of body iron is present as the storage iron, predominantly located in the macrophages of the reticulo-endothelial system and the hepatocytes of the liver (Anderson et al., 2007). The movement of iron in the human organism is a tightly regulated process, which can be modulated according to the iron requirements.

The recent advancements in the knowledge of the regulation of iron metabolism have made it possible to understand better the pathophysiology of some human disorders. The aim of this work was to present the current state of knowledge of the regulation of the human systemic iron homeostasis, without focusing on the diseases derived from the disturbances of this process.

Iron absorption in the duodenum
In most conditions, dietary iron is a critical determinant of the body’s iron status because once absorbed
it is not actively excreted (Wang and Pantopoulos, 2011). Iron absorption by enterocytes is programmed to match the body needs. There are two major signals that affect iron absorption. One of them reflects the need for iron due to erythropoiesis (red blood cells generation). The hormone erythropoietin (EPO), produced by the kidneys, stimulates red blood cells production, and can act directly on intestinal epithelial cells to increase dietary iron absorption for subsequent utilisation in the bone marrow. Until recently, it was believed that EPO is not a signal regulating the iron absorption. However, recent research has provided a novel insight into the mechanisms by which the body senses and responds to the changes in the erythroid requirements for iron (Chung et al., 2009).

Another signal depends on the amount of iron in body iron storages. If the level of body iron storage is low, iron absorption is stimulated. Such signal (and some others) regulates the iron absorption in the proximal duodenum, where the iron is absorbed.

The form of iron which is presented to the digestive tract affects iron absorption, and inorganic iron ions change the oxidation state during the absorption process. There are two forms of dietary iron, i.e. non-heme iron (ferric, Fe$^{3+}$) and heme iron (ferrous, Fe$^{2+}$) (Formanowicz et al., 2007).

Non-heme iron absorption

Non-heme iron is released by acid digestion in the stomach and must be reduced to the ferrous ion by reductases, prior to the uptake by duodenal enterocytes (intestinal epithelial cells responsible for nutrient absorption) (Theurl et al., 2005). Two ferric reductases are involved in this process: duodenal cytochrome b (DCYTB) and cytochrome b reductase-1 (CYBRD-1). Ferrous ions are transported across the enterocyte apical membrane by divalent metal transporter-1 (DMT-1) (Gunshin et al., 1997), a member of the solute carrier group (SLC) of membrane transport proteins. This transport protein is also known as a solute carrier family 11, member 2 (SLC11A2), natural resistance-associated macrophage protein-2 (Nramp2) or divalent cation transporter-1 (DCT-1), acting as a proton coupled divalent ion transporter. The amount of DMT-1 in the apical membrane is regulated by the body iron requirements. DMT-1 transport is pH dependent, optimal at acidic pH (5.5 to 6.0), electrogenic, and associated with the proton co-transport (Gunshin et al., 1997). Alternative splicing of the DMT-1 gene produces two isoforms distinguished by the presence (isoform I) or absence (isoform II) of an iron-responsive element (IRE) in the 3’ untranslated region (UTR), both being competent in the iron transport. DMT-1 synthesis is reduced in iron-enriched diets but increases when the iron intake is restricted (Canonne-Hergaux et al., 1999). The converse is true for the liver, since this organ acts as a reservoir of iron. High levels of dietary iron lead to an increase in DMT-1 synthesis in hepatocytes, promoting iron acquisition, whereas low levels lead to a decrease in hepatic DMT-1 synthesis, thus causing a reduction in iron accumulation (Trinder et al., 2000). Although kidneys are not usually associated with the serum iron balance, several studies have found renal DMT-1 accumulation in mice and rats, which suggest that this organ may play a role in iron homeostasis ( Ferguson et al., 2001; Veuthey et al., 2008). Recently it has been found that the suppression of SLC11A2 expression is essential for maintaining duodenal integrity during the dietary iron overload (Shirase et al., 2010). Studies in the animals carrying missense mutations in SLC11A2 have demonstrated two major roles for this transporter, i.e. the intestinal non-heme iron transport and the iron uptake (Gunshin et al., 2005). SLC11A2 has also been found in Tf cycle endosomes in erythroid precursors (Canonne-Hergaux et al., 2001), where it may participate in transfer of iron to the cytoplasm. Moreover, SLC11A2 was also revealed in hepatocytes, where it has been postulated to be involved in non-Tf-bound iron uptake (Trinder et al., 2000) and in the placenta, where it may participate in the materno-fetal iron transfer (Georgieff et al., 2000). After entering the cytoplasm of the intestinal cells, ferrous iron joins the cytosolic labile iron pool (LIP) and is finally exported across the enterocyte’s basolateral membrane to the circulation via ferroportin-1 (FPN-1). The absorbed iron may be stored bound to ferritin within the enterocyte, and is later lost when the intestinal mucosa is sloughed. The accumulation of iron will be discussed in Section: Iron distribution.

Heme iron absorption

The dietary heme iron absorption pathway is distinct from that of non-heme iron absorption (Wyllie and Kaufman, 1982). Heme iron, ingested as myoglobin and hemoglobin, is the most easily absorbed form. In the presence
An overall view of the process of the regulation of human iron metabolism

of gastric acid, the globin molecule is split off and ferrous iron is liberated and transported with its phospho-
rin ring from the stomach into the duodenum and jeju-
num. The mechanisms of absorption and uptake of heme by enterocytes and cultured cells have been studied for a long time. Currently, there are two prevailing hypo-
theses explaining the mechanisms of that process.

Firstly, there is a hypothesis that heme is taken up by receptor-mediated endocytosis (RME). The internali-
ized heme is degraded by heme oxygenase-2 (HO-2) insi-
de the endosomal vesicles, releasing non-heme iron and

generating biliverdin. The non-heme iron is then trans-
ported to the cytoplasm by DMT-1 (West and Oates,
2008), joins the LIP, and is finally transported to
the bloodstream by FPN-1.

Secondly, heme-iron may also be taken up directly
into the cytoplasm by a recently discovered heme trans-
porter – heme carrier protein-1 (HCP-1) (Shayeghi et al.,
2005). The role of HCP-1 in heme/iron biology was later
overshadowed by the finding that HCP-1 primarily func-
tions as an intestinal proton-coupled folate transporter
(PCFT) (Inoue et al., 2008). HCP-1 mRNA synthesis ap-
pears to be less responsive to iron deficiency (Latunda-
Dada et al., 2006) when compared to the non-heme im-
porter – DMT-1 mRNA synthesis (Sharp et al., 2002). It
is worth mentioning that studies regarding the full physio-
logical role of PCFT/HCP-1 in the heme metabolism are
still going on. The researchers propose that PCFT/HCP-1
functions in endosomes to export heme which is released
from hemoglobin:haptoglobin (Hb: Hp) complexes into
the cytosol for degradation by microsomal heme oxy-
genase (HO) (Schae et al., 2008). Heme, after entering
the cytoplasm, is taken by PCFT/HCP-1, and may be
catabolized to non-heme iron and biliverdin by an indu-
cible microsomal enzyme – heme oxygenase-1 (HO-1),
located in the endoplasmic reticulum. It allows heme
iron to enter the same LIP as non-heme iron. The syn-
thesis and function of PCFT/HCP-1 are shown to be
adaptive to the rate of heme degradation by HO-1
(Latunda-Dada et al., 2006). Alternatively, intact heme,
instead of being catabolized by HO-1, may be transported
directly to the bloodstream by the recently discovered
heme transporter called feline leukemia virus, subgroup
C receptor (FLVCR) (Quigley et al., 2004). This trans-
port requires an extracellular heme-binding protein such
as albumin or circulating hemopexin (HPX) since export
is not observed in the absence of a carrier protein (Yang
et al., 2010). HPX is present in the circulation at levels
similar to that of the Tf – iron transporter, suggesting
that the systemic circulation of heme bound to HPX (or
the more abundant plasma protein albumin) may be of
relevance to iron homeostasis (Khan and Quigley, 2011).
The presence of FLVCR in macrophages responsible for
the processing of senescent erythrocytes was also detect-
ed. It was found that iron derived from heme catabolism
is either exported by the phagocytic cell-specific divalent
metal transporter – natural resistance-associated macro-
phage protein-1 (Nramp-1) (Soe-Lin et al., 2009) and
FPN-1, or stored within ferritin. However, during ery-
throcytophagocytosis, not all the hemes appear to be
broken down by HO-1 (Knutson et al., 2005), and FLVCR
provides an important heme iron-export function that im-

pacts the systemic iron homeostasis (Keel et al., 2008).

Heme transport research is still ongoing and new
proteins are analyzed in this respect. Recently, the role
of the mitochondrial ATP binding cassette transporters,
such as ATP-binding cassette sub-family B member 6, 7,
10 (ABCB6, ABCB7, ABCB10, respectively), in transport
of heme biosynthesis intermediates has been studied.
ABCB7 – appears to be important for cytosolic but not
mitochondrial Fe–S cluster biogenesis. Both ABCB6 and
ABCB10 are proteins consistently co-expressed with
heme synthesis pathway enzymes, suggesting a role for
these proteins in heme metabolism. A physiological sub-
strate of ABCB6, relevant to heme synthesis, has yet to
be identified. Another protein – ATP-binding cassette
sub-family G member 2 (ABCG2) also known as mitoxan-
trone resistance protein, breast cancer resistance pro-
tein, and placenta-specific ABC transporter (MXR,
BCRP, and ABCP respectively) located in plasma mem-
brane are found to be potentially responsible for heme
exports (Khan and Quigley, 2011).

Although in the last few years, the knowledge of
the heme physiology has increased vastly, the fundamen-
tal questions still remain unanswered. They include the
identity of transporters involved in the transfer of heme
and heme intermediates across the mitochondrial mem-
branes, the sites of heme transfer to apoproteins,
the identity of intracellular heme chaperones, the com-
parative contributions of FLVCR and the HO system to
cellular protection from oxidative stress and/or heme
excess, and the role of the systemic circulation of heme
in iron homeostasis and its other functions (Khan and
Quigley, 2011).
A schematic diagram showing the regulation of iron efflux from enterocytes and macrophages, based on the current knowledge, has been presented in Figure 1.

**Ferroportin – hepcidin axis determinates plasma iron concentration**

**Ferroportin – an iron exporter**

Iron efflux from the enterocyte basolateral membrane is performed by membrane-bound ferrous iron transporter – FPN-1, also known as iron-regulated transporter-1 (IREG-1), metal transporter protein-1 (MTP-1) or the product of solute carrier family 40, member 1 gene (*SCL40A1*) (Donovan A. et al., 2000) previously called as solute carrier family 11, member 3 gene (*SCL11A3*). This protein has been independently identified by three groups of researchers who used different approaches (Abboud and Haile, 2000; Donovan et al., 2000; McKie et al., 2000). FPN-1 is synthesized in many iron-exporting cells, including hepatocytes, macrophages – where FPN-1 exports iron from the cytosol into the bloodstream (for iron recycling), and placental syncytiotrophoblasts. Thus, it not only plays a fundamental role in the release of iron from tissues, but also in maternal iron transfer to the fetus (Donovan et al., 2005; McKie and
Barlow, 2004). There is evidence that FPN-1 is also synthesized in renal cells located in the glomerulus and proximal tubular cells of this tissue but its role remains obscure (Wolff et al., 2011).

The FPN-mediated efflux of Fe^{2+} from enterocytes and macrophages, which is responsible for clearing senescent red blood cells into the plasma, is critical for the systemic iron homeostasis. Afterwards, iron is oxidized by a membrane bound ferroxidase – hephaestin (HEPH), that physically interacts with FPN-1 yielding ferric ions that are then bound by plasma Tf and distributed around the body via blood (Theurl et al., 2005; Yeh et al., 2009). It should also be noted that Fe^{3+} transported by FPN-1 must first be reduced by a ceruloplasm (Cp) homologue - hephaestin (HEPH) (Vulpe et al., 1999), mostly synthesized in the small intestine and colon, to be prepared for Tf transport. So, the rate of absorption of iron by enterocytes in the human organism, a key regulation point of systemic iron metabolism, is controlled by the activity of the two membrane transporters, i.e. DMT-1 and FPN-1. A very interesting and still poorly understood issue is the regulation of FPN-1 expression. It is regulated at several levels (Zhang et al., 2009), including transcriptional regulation in the duodenal mucosa and macrophages (McKie et al., 2000; Knutson et al., 2003), translational regulation by the iron-regulatory element/iron-regulatory protein (IRE/IRP) system (McKie et al., 2000; Abboud and Haile, 2000; Lymboussaki et al., 2003), and post-translational regulation by hepcidin, secreted by hepatocytes in response to increased iron abundance (Park et al., 2001; Pigeon et al., 2001; Krause et al., 2000). This protein is encoded in humans by the hepcidin antimicrobial peptide (HAMP) gene, initially identified as liver-derived antimicrobial peptide (LEAP). Its name originates from the place of the synthesis in hepatocytes (hep-) and its antimicrobial activity (-cidin) (Politou M. and Papanikolaou, 2004). Hepcidin is primarily expressed in the liver as a precursor pro-peptide. Pro-hepcidin undergoes proteolytic processing to yield a bioactive molecule of 25 amino acids that is secreted into the bloodstream (Wang and Pantopoulos, 2011). The mature hormone circulates in plasma and binds to α_{2}-macroglobulin (Peslova et al., 2009). While this interaction was shown to promote hepcidin activity in vitro, the effect on hepcidin clearance is still unknown. A major route of hepcidin clearance is renal excretion. However, it may also be cleared by RME in tissues expressing its receptor FPN-1, as indicated by the accumulation of radiolabeled hepcidin in FPN-1-rich tissues (Nemeth and Ganz, 2009).

Both transcriptional and post-transcriptional mechanisms have been implicated in the regulation of FPN-1. They are induced by changes in the cellular iron status. Recently, in the duodena of iron-deficient mice, an FPN-1 transcript – ferroportin-1B (FPN-1B) which lacks IRE, so it is not regulated by the IRE/IRP system, has been identified (Zhang et al., 2009). Alternative transcripts of FPN-1 have been previously observed in human erythroid cells (Cianetti et al., 2005; Cianetti et al., 2010). On the basis of these findings, researchers (Zhang et al., 2009) proposed an updated model of duodenal iron uptake, which expands the hepcidin-FPN-1 interaction model. During iron-replete conditions, both FPN-1 transcripts, i.e. FPN-1A and FPN-1B are translated into FPN-1 protein, which traffics to the basolateral membrane of the intestine to transport iron into the bloodstream. Once the iron stores are high, the liver produces hepcidin, which causes FPN-1 degradation and blocks iron absorption (Nemeth et al., 2004). During iron-deficient conditions, hepcidin expression decreases and the systemic iron-uptake blockage created by degradation of FPN-1 is eliminated. Iron deficiency state activates the IRE/IRP system, which then represses the translation of FPN-1A. In iron deficiency anaemia, the expression of FPN-1B increases markedly (as does FPN-1A) and its ability to be translated into protein, regardless of IRP repressor activity, likely enables it to generate enough FPN-1 to satisfy the systemic iron demands (Zhang et al., 2009).
tion (Nemeth et al., 2004; Singh et al., 2011; Franchini et al., 2010; Hentze et al., 2010).

In the recent past, major advances have been made in understanding the molecular mechanism of hepcidin regulation. The expression of hepcidin is controlled transcriptionally. Basal hepcidin transcription requires CCAAT/enhancer-binding protein-α (C/EBPα) that belongs to a family of transcription factors that are critical for cellular differentiation and terminal function and inflammatory response (Courseslaud et al., 2002). Hepcidin synthesis is modulated in response to several conditions, such as inflammatory process, iron stores (Pigeon et al., 2001), hypoxia and anemia (Nicolas et al., 2002). During inflammation, the availability of iron from stored forms and iron absorption tends to decrease leading to an increase in the amount of stored iron, which induces hepcidin synthesis. The disruption of hepcidin is associated with a systemic iron overload (hemochromatosis) (Lee and Beutler, 2009), whereas pathological elevation of hepcidin levels contributes to the development of an anemia of chronic disease (ACD) (Weiss and Goodnough, 2005) and a hereditary iron-refractory iron deficiency anemia (IRIDA) (Finberg, 2009; Weinstein et al., 2002).

Like other hormones, hepcidin is feedback-regulated by the substances whose concentration it controls, i.e. iron. This requires substances that function as intracellular and extracellular iron sensors coupled to transduction pathways that regulate its synthesis or secretion by the liver (Ganz and Nemeth, 2011). Studies related to primary hepatocytes show that hepcidin responds to oral iron as normal individuals do (Piperno et al., 2007). In vivo, the hepcidin response to dietary iron is proportional to the increase in the amount of iron carried by plasma Tf (i.e., transferrin saturation (TSAT)). The possible mechanism of this process is a cross-talk between the bone morphogenetic protein (BMP) and the mitogen-activated protein kinase (MAPK) signaling (Ramey et al., 2009). The BMP pathway, involved in cell proliferation, differentiation, and apoptosis, seems to be specifically regulated through a combination of two main factors: bone hemojuvelin (HJV) and morphogenetic protein-6 (BMP-6). HJV exists bound to the cell surface (a BMP membrane-anchored coreceptor) or in a circulating soluble form (sHJV) processed by furin. sHJV down-regulates hepcidin in a competitive way interfering with BMP signaling (Silvestri et al., 2008). Thus, cell-surface HJV binds to BMP and stimulates BMP signaling and hepcidin synthesis, whereas the soluble form antagonizes this effect. Any stimulus that leads to increased synthesis of sHJV, lead to a reduction of hepcidin expression as well. It was found that iron treatment and hypoxia increases the generation of sHJV (Silvestri et al., 2008). As mentioned above, in addition to HJV, the second important factor that regulates human iron homeostasis is BMP. Iron triggers the expression of an iron-specific ligand – BMP6 in the liver and in the intestine, which is thought to be secreted into the plasma for binding to a BMP receptor (BMPR) on the hepatocytes surface. BMP6 signaling leads to the utilization of cytoplasmic proteins, called SMADs by phosphorylation of SMAD1/5/8 (Kautz L. et al., 2008) and translocation of SMAD family member 4 (SMAD4) to the nucleus (Wang et al., 2005; Meynard et al., 2009). In the nucleus, it promotes hepcidin transcription upon binding to proximal and distal sites on its promoter (Wang and Pantonopoulos, 2011). Other BMPs, including BMP2, 4, 5, 7, 9 also have the ability to induce hepcidin expression, in vitro (Xia et al., 2008; Truksa et al., 2006), but their role in vivo still requires explanation. The last clinical findings suggest that the liver uses TSAT as an iron sensor. At the cellular level, iron sensing appears to involve transferrin receptor-2 (TfR2) because liver-specific disruption of TfR2 in mice markedly diminished hepcidin expression despite hepatic iron overload and substantially elevated TSAT (Collins et al., 2008). Moreover, the hemochromatosis protein (HFE) appears to be required for iron sensing because it was disclosed that patients with HFE mutations do not produce hepcidin in response to oral iron as normal individuals do (Piperno et al., 2007). In vivo studies suggest that HFE induces hepcidin expression only when it is not in complex with TfR1 (Collins et al., 2008; Schmidt et al., 2008). However, in vitro studies that show an interaction between HFE and TfR2 suggest that these molecules cooperate together to sense iron. It has been therefore proposed that HFE uncouples from TfR1 to form the HFE/TfR2/differetiT complex that enables up-regulation of hepcidin expression. This in turn, leads to a decrease in dietary iron uptake and reduction in iron recycling from macrophages in response to TSAT (Collins et al., 2008; Schmidt et al., 2008; Gao et al., 2009). It is possible that this complex potentiates BMP and/or MAPK pathway signaling. Whether HFE and TfR2 directly interact with BMP receptors and HJV, or initiate a separate signaling cascade needs to be
elucidated. Furthermore, in the response to Tf, hepatocytes can also increase the synthesis of hepcidin in response to stored intracellular iron. The mechanism of this process is still unclear, but some studies suggest that BMP6 concentration could reflect the intracellular iron levels in the hepatocyte.

Although hepcidin expression is expected to be low in iron deficiency, some clinical situations are more complex. Only recently, studies involving patients with iron-refractory anemia (IRA), have indicated a possibility of coexistence of high levels of hepcidin expression and iron deficiency. This helped to discover the role of transmembrane protease, serine 6 (TMPRSS6) in the regulation of hepcidin during iron deficiency. TMPRSS6 is expressed in the liver. Recent studies suggest that TMPRSS6 normally acts to down-regulate hepcidin expression by cleaving HJV (Silvestri et al., 2008).

As mentioned above, the inflammatory process has the ability to stimulate hepcidin. The inflammatory regulation of hepcidin gene expression involves transcriptional control through a signal transducer and activator of transcription (STAT) site located on the hepcidin promoter. It was found that the pro-inflammatory cytokine interleukin-6 (IL-6) can influence hepcidin expression through the janus kinase – signal transducer and activator of transcription (JAK-STAT) signaling pathway, but this stimulation is dependent on an intact BMP-SMAD pathway as well (Darshan and Anderson, 2009). So, stimulation of IL-6 synthesis induces hepcidin transcription via a signal transducer, an activator of transcription-3 (STAT3) phosphorylation and translocation to the nucleus for binding to a proximal promoter element (Wang and Pantopoulos, 2011). Interestingly, IL-6 induction of hepcidin gene expression appears to be inactive when the signaling of hepatic SMAD4 is impaired (Wang et al., 2005), and lipopolysaccharide (LPS)-induced hepcidin up-regulation is attenuated by deficiency in BMP6 (Meynard et al., 2009). This indicates that SMAD signaling plays a key role in staging the appropriate response to inflammation (Wessling-Resnick, 2010). Furthermore, another cytokine, i.e. interleukin-1β (IL-1β) activates hepcidin via the C/EBPα and BMP/SMAD pathways (Matak et al., 2009). It should also be mentioned that endoplasmic reticulum stress turns on hepcidin transcription via cyclic AMP response element-binding protein H (CREBH) and/or C/EBP homologous protein (CHOP) (Vecchi et al., 2009; Oliveira et al., 2009). LPS promotes hepcidin activation in macrophages via toll-like receptor 4 (TLR4) signaling (Peyssonnaux et al., 2006), whereas the pathogen *Borreli burgdorferi* activates myeloid hepcidin via toll-like receptor 2 (TLR2) (Köning et al., 2009). Moreover, EPO signaling through erythropoietin receptor (EPO) down-regulates hepcidin following the decreased binding of C/EBPα to its promoter (Pinto et al., 2008). Hepcidin transcription is also suppressed by hypoxia and oxidative stress. The hypoxia-inducible factors (HIF) pathway was shown to regulate hepcidin expression, *in vivo* (Volke et al., 2009; Nemeth, 2008). However, the role of HIFs in the hypoxic pathway of hepcidin is still not fully understood.

A scheme of the hepcidin regulation when diferric Tf concentration is high has been presented in Figure 2.

### Transportation of iron ions by transferrin

Tf is the main serum iron transporter in all vertebrates. It takes up iron from duodenal enterocytes where iron is absorbed, and from macrophages when iron is recycled from senescent red blood cells, and delivers it to cells by binding TfR1. Physiologically, in a reaction with Concanavalin A, Tf occurs in four distinct variants: Tf1, Tf2, Tf3 and Tf4. Although we have little information about the participation of individual variations in the transport of iron, changes in their proportions seem to be important in maintaining the iron disturbances in chronic kidney disease (CKD) (Formanowicz and Formanowicz, 2011a). The Tf occupancy reflects the balance of iron entering the serum (from intestinal absorption, macrophage iron release, and hepatic iron mobilization) and iron leaving the serum (primarily for utilization in erythropoiesis). Iron uptake starts when Tf-Fe³⁺ binds TfR1. Under normal circumstances, all of non-heme iron in the circulation is bound to holotransferrin (HoloTf). Only about 30% of Tf-binding sites are occupied, so that most of the protein, which is called apotransferrin (ApoTf), is free of iron and is able to bind one or two Fe³⁺ ions at transferrins N- and/or C-terminal ends: (Nt(Fe³⁺)HoloTf or HoloTf (Fe³⁺)Ct or HoloTf(Fe³⁺)₂) (Formanowicz et al., 2007). Monoferric Tf is the predominant form of Tf in circulation when transferrin saturation is lowered (Cazzola et al., 1987). However, each molecule of monoferric transferrin delivers less iron to erythroid precursors than diferric transferrin does (Huebers et al., 1984).
**Fig. 2.** Hepatic hepcidin regulation when diferric Tf concentration is high (based on Nemeth E., 2008). Diferric Tf binds to transferrin receptors 1 and 2 (TfR1 and TfR2 respectively). As a result, TfR2 is stabilized and human hemochromatosis protein (HFE) dissociates from TfR1 and binds to TfR2. The HFE/TfR2 complex interacts with hemojuvelin (HJV), and less soluble HJV (sHJV) having ability to inhibit bone morphogenic protein signaling (BMP) pathway is generated. Thus, the BMP signaling pathway is intensified. Finally, it leads to the utilization of cytoplasmic proteins, called SMADs by their phosphorylation and translocation of SMAD family member 4 (SMAD4) to the nucleus, which results in increased hepcidin transcription.

TfR1 has much higher affinity for Fe-Tf than for ApoTf, which suggests that the competition between HFE and Tf for TfR1 binding might be modulated by Tf occupancy with iron. Furthermore, the fact that TfR2 expression is induced by Fe-Tf suggests that the HFE/TfR2 interaction may also be altered by TSAT. It was hypothesized that the purposes of the HFE/TfR1 and HFE/TfR2 interactions might therefore be the regulation of the hepcidin expression in response to body iron status (Schmidt et al., 2008).

On the cell surface, iron-bound HoloTf binds to TfR1 and as the HoloTf(Fe\(^{3+}\))-TfR1 complex is internalized, into endosomes by RME process through clathrin coated pits (Chung et al., 2009). After internalization of this complex, iron Fe\(^{3+}\) is released from HoloTf under the endosomal acidic conditions, then occurs in the reduced form as Fe\(^{2+}\) and forms ApoTf. Next, ApoTf and TfR1 complex (ApoTf-TfR1) is exocytosed. After the return of the complex to the cell surface, the extracellular pH triggers the release of ApoTf, allowing another round of binding and RME to begin.

**Iron distribution**

Iron distribution into body periphery is a complex issue. And so, one may distinguish flux through the erythron, flux through peripheral compartments with storage function (liver, muscles, intestinal tract, kidney, heart, lungs) and flux through organs with slow iron turn-over (testicles, fat, brain) (Lopes et al., 2010). The prevailing view is that all forms of iron entering cells reach a cytosolic pool of metabolically active or labile iron. This viewpoint will be discussed in the next section.

Iron gains entry into erythroid precursors when Tf-Fe\(^{3+}\) binds TfR1, but what controls this distribution of iron to erythroid precursors is not completely understood (Li and Ginzburg, 2010). The amount of iron delivered to each erythroid precursor depends on the amount of monoferric and diferric Tf found in circulation as well as the density of TfR1 on the cell surface. Typically, each erythroid precursor has over a million TfR1s on its membrane because of its large iron requirement for hemoglobin synthesis, relative to all other cells in the body (Muckenthaler et al., 2008).
The mechanism by which cells alter their TfR1 expression involves iron regulatory proteins (IRPs) which have a high affinity for IREs present in the mRNA of target genes involved in iron homeostasis. If an IRE is at the 5’ UTR, mRNA is more likely to be degraded and translation is blocked, whereas if it is at the 3’ UTR, it is more likely to be stabilized and translation is more efficient as a result of IRP binding. Thus, in an iron-depleted state, when IRPs are able to bind mRNA, ferritin mRNA with a 5’ UTR IRE is more likely to be degraded while TfR1 mRNA with a 3’ UTR IRE proceeds to translation more readily (Yeh et al., 2009). As a consequence of IRE/IRP regulation, iron deficiency is associated with high TfR1 expression and low ferritin concentrations (Murray-Kolb et al., 2003).

Iron in erythroid precursors is then transported to mitochondria for heme synthesis. Heme not participating in hemoglobin synthesis results in a down-regulation of IRP2 which reduces TfR1 expression at the cell surface and thus the amount of iron entering cells (Li and Ginzburg, 2010). Ferritin is the major protein used for intracellular storage of iron. It serves to store iron in a non-toxic form and transports it to various tissues. However, the cellular mechanism used to absorb ferritin iron is still unknown. Since ferritin iron can be absorbed from soybean ferritin (SBFn), even in the presence of iron-binding inhibitors such as phytate (Murray-Kolb from soybean ferritin (SBFn), even in the presence of iron-binding inhibitors such as phytate (Murray-Kolb et al., 2003; San Martin et al., 2008), it is possible that at least part of the ferritin iron is absorbed by a mechanism distinct from transport of lower molecular weight iron complexes. High-affinity mammalian ferritin-binding sites have been reported in reticulocytes, lipocytes, hepatocytes, placenta, brain and kidney, although the mechanism of ferritin endocytosis has not been elucidated. Previous studies have indicated that iron may be taken up from ferritin via a ferritin receptor (Liao et al., 2001) and recent kinetic data supports these findings. A specific ferritin receptor has been found in Caco-2 cells (Kalgaonkar and Lönnerdal, 2009). It was also discovered that uptake of iron from ferritin affects the expression of iron transporters in a manner different from iron presented as ferrous sulfate. This supports the hypothesis that an uptake mechanism for ferritin iron differs from that for ferrous iron. So, it is possible that iron is taken up from intact (or partially digested) ferritin via endocytosis or that iron is released from ferritin and taken up as ferrous iron by DMT-1. It is not yet known if iron in the mineral core is released after ferritin digestion or if this mineral core remains intact for some time and is taken up by some yet unknown mechanism. It is also possible that iron is taken up from ferritin via a combination of these pathways, which may explain its high bioavailability (Lönnerdal, 2009).

Ferritin serves as the depot site for iron storage during sequestration responses caused by inflammatory response. In addition to the control by IRP of the actions triggered by iron in the liver and in other tissues, inflammatory cytokines regulate IRE/IRPs ferritin translation through an “acute-phase box” in the 5’ region of its transcript (Torti and Torti, 2002). The mechanisms of transcriptional control serve to further up-regulate ferritin expression, and increased serum ferritin levels are well recognized as a part of the acute-phase response (Wessling-Resnick, 2010; Torti and Torti, 2002). Ferritin serves as a suppressor of the reactive oxygen species (ROS) generation by sequestration of intracellular excess free-iron. The oxidative stress-mediated regulation of ferritin and frataxin – a mitochondrial protein that appears to regulate iron homeostasis and oxidative stress in mitochondria is now thoroughly tested. The function of frataxin is not fully explained but it seems to be involved in the assembly of Fe-S clusters. It has been proposed that it either acts as an iron chaperone or as an iron storage protein (Adinolfi et al., 2009).

The majority of intracellularly stored iron is found in liver, skeletal muscle and reticuloendothelial cells. If the storage capacity of ferritin is exceeded, iron will deposit adjacent to the ferritin-iron complexes in the cell. Histo logically, those amorphous iron deposits are referred to as hemosiderin. Hemosiderin is composed of ferritin, denatured ferritin, and other materials, but its molecular structure is poorly defined. The iron present in hemosiderin is not readily available to the cell and thus cannot supply iron to the cell when it is needed. Hemosiderin is most frequently found in macrophages and is most abundant after hemorrhagic events.

**Labile iron pool**

The labile iron pool (LIP) is a compartment from which most of the metal is either metabolically drawn into Fe-dependent enzymes, transported into mitochondria for heme synthesis or incorporated into ferritin for secure storage and/or detoxification. LIP is composed of forms of iron bound to a variety of medium and low af-
finity binding ligands. It might vary in composition and quantities in different physiological settings. Operationally, LIP can be regarded as that component of cell iron that is accessible to a particular chelator or a class of chelators. Topologically, it is identified primarily with the cytosol and as such, it is regarded as the crossroad of cellular iron traffic (Chung et al., 2009). Biochemically, LIP has been defined as the ‘regulatory’ or ‘regulated’ pool of cell iron, since depending on the cells system, its level is apparently maintained within a constant range.

The labile nature of LIP was also revealed by its capacity to promote the formation of ROS, whether from the endogenous or exogenous redox-active sources. LIP and ROS levels were shown to follow similar “rise and fall” patterns as a result of changes in iron import vs. iron chelation or ferritin degradation vs. ferritin synthesis. Those patterns conform with the accepted role of LIP as a self-regulatory pool that is sensed by cytosolic IRPs and feedback regulated by IRP-dependent expression of iron import and storage machineries. However, LIP can also be modulated by biochemical mechanisms that override the IRP regulatory loops and, thereby, contribute to basic cellular functions (Kakhlova and Cabantchik, 2002).

The formal model of the process

As can be seen from the previous sections, the regulation of iron metabolism is a very complex process. Probably, most of the components of this process are known but we cannot be sure that all of them have already been discovered. Hepcidin, which has been known for only a few years, may serve as an example supporting the hypothesis that it is possible that even very important components of iron homeostasis process may still wait for being discovered. Moreover, not only the components of the process but also the dense network of interactions among them is crucial for the proper regulation of iron metabolism. The latter is a special case of a more general rule which becomes more and more obvious. According to this rule most of the biological processes are, in fact, complex systems whose nature and functionality is a reflection of the interactions taking place among their elements. Hence, a detailed analysis of such systems requires proper mathematical and computational tools. The basis of such an analysis is a precise model of the studied system. Such a model can be expressed as ordinary differential equations which are quite often used to model biological phenomena. However, models based on equations of this type usually require precise values of some parameters. Unfortunately, these values are often difficult to obtain in practice, which limits the application of the models. An interesting alternative for models based on differential equations are models based on a graph theory. The latter ones usually describe qualitative rather than quantitative properties of the analyzed system, so it is possible to abstract (at least to some extent) from exact values of parameters required by differential equations. In addition, graphs very well match the network structure of the interactions taking place among the elementary components of biological systems. What is more, graphs are very similar to the network structure. So, it should not be surprising that they are more and more often used in systems approach to the analysis of biological phenomena.

One of the special cases of graph theory based models are those which are expressed in the language of Petri nets theory. Such nets are composed of vertices of two types, called places and transitions, connected by arcs in such a way that if a starting vertex of an arc is a place then its ending vertex is a transition and vice versa. In a biological context, the transitions represent some reactions while the places correspond to components needed for a reaction to take place or produced as a result of its execution. As it is easy to guess, arcs represent causal relations between components and reactions (for more details see Błażewicz et al., 2009a; Sackmann et al., 2007).

The Petri net theory has been recently used to formulate a precise model of the main part of the iron metabolism process (Formanowicz et al., 2007; Sackmann et al., 2007). The model describes detailed qualitative relationships between the elementary components of the process in a mathematically rigorous way, which at the same time, is relatively easy to understand even for those who are not familiar with the graph theory. Despite the fact that many processes involved in iron metabolism have been described in literature, this model is the first mathematical description of the human iron homeostasis (see Curis et al., 2009) for a recent review of mathematical modeling of metal metabolism). One of the advantages of the Petri net based models is the availability of many software tools for simulation and analysis of formal properties of the models, which may
lead to discoveries of some biological properties not yet known. The first model of iron metabolism has been extended by inclusion of available knowledge of hepcidin (Sackmann et al., 2009) and some time dependencies (Blażewicz et al., 2009b). It may be a basis for a detailed analysis of the regulation of iron metabolism which would be impossible without such a formal description of the process. The model is a starting point for an analysis characteristic for systems biology where an investigation of formal properties of the theoretical model of a biological system leads to discovering unknown aspects of the system. The analysis allows to observe complex relationships between different parts of the modeled system which are difficult to discover without an application of formal methods. Although that model is only the first step in this direction, some biological discoveries have already been made on this basis (Formanowicz et al., 2011b).

It is worth mentioning that the development of a mathematical model of a biological system and the discovery of some unknown features of the system on the basis of that model is, in general, an iterative and cyclic process. Indeed, when the model is formulated, an analysis of its formal properties may lead to discoveries of some new properties of the system. These properties may be then verified in laboratory experiments or through clinical data. The obtained results may lead to the creation of a more precise model. A more accurate model may subsequently make new discoveries possible. After all, the amount of available information on the analyzed system increases as a result of this iterative process.

**Conclusions**

In this work, the main part of the whole process of the regulation of iron metabolism has been presented. The paper highlights the importance of many proteins, among others, hepcidin, ferroportin, transferrin, involved in maintaining iron balance in the human body. Knowledge of iron metabolism has been considerably expanded in recent years. The application of new techniques has enabled the detection of novel interactions between various elements of this complex puzzle of iron homeostasis maintenance. Moreover, computational and systems biology approaches for studying biological phenomena have been recently applied to the analysis of iron homeostasis. This opens new possibilities towards complete understanding of the complex and crucial biochemical process that is being considered in this paper.

**Acknowledgements**

This work was partially supported by the Polish Ministry of Science and Higher Education grant no. NN 402 2098 33.

**Abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABCB6</td>
<td>ATP-binding cassette, sub-family B, member 6</td>
</tr>
<tr>
<td>ABCB7</td>
<td>ATP-binding cassette, sub-family B, member 7</td>
</tr>
<tr>
<td>ABCB10</td>
<td>ATP-binding cassette, sub-family B, member 10</td>
</tr>
<tr>
<td>ABCG2</td>
<td>ATP-binding cassette sub-family G member 2</td>
</tr>
<tr>
<td>ABCP</td>
<td>placenta-specific ABC transporter</td>
</tr>
<tr>
<td>ACD</td>
<td>anemia of chronic disease/anemia of chronic disorders</td>
</tr>
<tr>
<td>ApoTf</td>
<td>apotransferrin</td>
</tr>
<tr>
<td>BCRP</td>
<td>breast cancer resistance protein</td>
</tr>
<tr>
<td>BMP</td>
<td>bone morphogenetic protein</td>
</tr>
<tr>
<td>BMP2</td>
<td>bone morphogenetic protein-2</td>
</tr>
<tr>
<td>BMP4</td>
<td>bone morphogenetic protein-4</td>
</tr>
<tr>
<td>BMP5</td>
<td>bone morphogenetic protein-5</td>
</tr>
<tr>
<td>BMP6</td>
<td>bone morphogenetic protein-6</td>
</tr>
<tr>
<td>BMP7</td>
<td>bone morphogenetic protein-7</td>
</tr>
<tr>
<td>BMP9</td>
<td>bone morphogenetic protein-9</td>
</tr>
<tr>
<td>BMPR</td>
<td>bone morphogenetic protein receptor</td>
</tr>
<tr>
<td>C/EBPα</td>
<td>CCAAT/enhancer-binding protein α</td>
</tr>
<tr>
<td>CHOP</td>
<td>C/EBP homologous protein</td>
</tr>
<tr>
<td>Cp</td>
<td>ceruloplasmin</td>
</tr>
<tr>
<td>CREBH</td>
<td>cyclic-AMP response element-binding protein H</td>
</tr>
<tr>
<td>CYP11B2</td>
<td>cytochrome b reductase-1</td>
</tr>
<tr>
<td>DCT-1</td>
<td>divalent cation transporter-1</td>
</tr>
<tr>
<td>DCTYB</td>
<td>duodenal cytochrome b</td>
</tr>
<tr>
<td>DMT-1</td>
<td>divalent metal transporter-1</td>
</tr>
<tr>
<td>EPO</td>
<td>erythropoietin</td>
</tr>
<tr>
<td>EPOR</td>
<td>erythropoietin receptor</td>
</tr>
<tr>
<td>FLVCR</td>
<td>feline leukemia virus, subgroup C receptor</td>
</tr>
<tr>
<td>FPN-1</td>
<td>ferroportin-1</td>
</tr>
<tr>
<td>FPN-1A</td>
<td>ferroportin-1A</td>
</tr>
<tr>
<td>FPN-1B</td>
<td>ferroportin-1B</td>
</tr>
<tr>
<td>HAMP</td>
<td>hepcidin antimicrobial peptide</td>
</tr>
<tr>
<td>Hb</td>
<td>hemoglobin</td>
</tr>
<tr>
<td>HCP-1</td>
<td>heme carrier protein-1</td>
</tr>
<tr>
<td>HEPH</td>
<td>hephaestin</td>
</tr>
<tr>
<td>HFE</td>
<td>human hemochromatosis protein</td>
</tr>
<tr>
<td>HIFs</td>
<td>hypoxia-inducible factors</td>
</tr>
<tr>
<td>HJV</td>
<td>hemoujuevin</td>
</tr>
<tr>
<td>HO</td>
<td>heme oxygenase</td>
</tr>
<tr>
<td>HO-1</td>
<td>heme oxygenase-1</td>
</tr>
<tr>
<td>HO-2</td>
<td>heme oxygenase-2</td>
</tr>
<tr>
<td>HoloTf</td>
<td>holotransferrin</td>
</tr>
<tr>
<td>Hp</td>
<td>haptoglobin</td>
</tr>
<tr>
<td>HPX</td>
<td>hemopexin</td>
</tr>
<tr>
<td>IL-1β</td>
<td>interleukin-1β</td>
</tr>
<tr>
<td>IL-6</td>
<td>interleukin-6</td>
</tr>
<tr>
<td>IRE</td>
<td>iron-responsive element</td>
</tr>
</tbody>
</table>
IREG-1  iron-regulated transporter-1
IRA  iron-refractory anemia
IRIDA  iron-refractory iron deficiency anemia
IRP  iron-regulated protein
JAK-STAT  janus kinase – signal transducer and activator of transcription
LEAP  liver-derived antimicrobial peptide
LIP  labile iron pool
LPS  lipopolysaccharide
MAD  mothers against decapentaplegic
MAPK  mitogen-activated protein kinase
MTF-1  metal transporter protein-1
MRX  mitoxantrone resistance protein
Nramp-1  natural resistance-associated macrophage protein-1
Nramp2  natural resistance-associated macrophage protein-2
PCTF  proton-coupled folate transporter
RME  receptor-mediated endocytosis
ROS  reactive oxygen species
SBFn  soybean ferritin
SLC  solute carrier group of membrane transport proteins
SLC40A1  solute carrier family 40, member 1
SLC11A2  solute carrier family 11, member 2
SLC11A3  solute carrier family 11, member 3
sHJV  soluble hemojuvelin
SMADs  homologs of both the drosophila protein, mothers against decapentaplegic (MAD) and the Caenorhabditis elegans protein SMA. The name is a combination of the two
SMAD4  SMAD family member 4
STAT3  signal transducer and activator of transcription-3
Tf  transferrin
TIR1  transferrin receptor-1
TIR2  transferrin receptor-2
TGF-β  transforming growth factor beta
TNF-α  tumor necrosis factor alpha
TLR2  toll-like receptor 2
TLR4  toll-like receptor 4
TMPRSS6  transmembrane protease, serine 6
TSAT  transferrin saturation

References


An overall view of the process of the regulation of human iron metabolism


